
Sonomotion
Developing Innovations in Non-Invasive Kidney Stone Treatment.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | $12.4m | Series C | |
Total Funding | 000k |
Related Content
SonoMotion is a medical device company that has developed a non-invasive platform for the treatment of kidney stones. The company's product line includes the Break Wave™ system, which uses lithotripsy to fragment kidney stones, and the Stone Clear device, which has received FDA de novo clearance for the non-invasive treatment of post-lithotripsy kidney stone fragments.
The company's technology is designed to be used on fully awake patients in various clinical settings, which could potentially reduce the need for more invasive procedures and anesthesia. SonoMotion has been actively engaged in clinical trials to validate its technology, having completed enrollment in a pivotal trial for its Break Wave™ system. The company has also secured funding through grants, including a $2.2 million Fastrack NIH SBIR grant, to support the development of its products.
The target market for SonoMotion's products includes hospitals, urology clinics, and other healthcare facilities that treat patients with kidney stones. The business model is likely based on the sale of its medical devices to these healthcare providers. By offering a non-invasive solution, SonoMotion aims to improve patient outcomes and reduce healthcare costs associated with kidney stone treatment.
Keywords: kidney stones, medical devices, non-invasive treatment, lithotripsy, urology, FDA clearance, clinical trials, healthcare technology, patient care, medical innovation